Patients’ own cells transformed into model for studying disease and developing potential treatment
Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. The approach, the first of its kind, takes advantage of induced pluripotent stem (iPS) cell technology to transform skin cells into retinal cells, which are then used as a patient-specific model for disease study and preclinical testing.
Using this approach, researchers led by Stephen H. Tsang, MD, PhD, showed that a form of RP caused by mutations to the gene MFRP (membrane frizzled-related protein) disrupts the protein that gives retinal cells their structural integrity. They also showed that the effects of these mutations can be reversed with gene therapy. The approach could potentially be used to create personalized therapies for other forms of RP, as well as other genetic diseases. The paper was published recently in the online edition of Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
“The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient’s genetic deficiency provides yet another tool for advancing the field of personalized medicine,” said Dr. Tsang, the Laszlo Z. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology.
Read more . . .
The Latest on: Personalized Gene Therapy
[google_news title=”” keyword=”Personalized Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized Gene Therapy
- Pfizer Gets FDA Approval For Rare Inherited Bleeding Disorder Gene Therapyon April 26, 2024 at 1:39 pm
In announcing its approval on Friday, the Food and Drug Administration said it had approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first gene therapy to ...
- US Approves Gene Therapy Treatment For Hemophiliaon April 26, 2024 at 11:04 am
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday.
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia Bon April 26, 2024 at 7:45 am
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the ...
- Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per doseon April 26, 2024 at 7:19 am
Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. | Ten years after dipping its toe ...
- FDA approves Beqvez gene therapy for adults with hemophilia Bon April 26, 2024 at 6:39 am
Beqvez is indicated for those on preventive treatment with a factor IX replacement therapy or have had life-threatening bleeding episodes.
- US FDA approves Pfizer's gene therapy for rare bleeding disorderon April 26, 2024 at 3:17 am
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a ...
- Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapieson April 25, 2024 at 6:38 am
Walgreens Boots Alliance (WBA) expands specialty pharmacy services with dedicated unit for gene and cell therapy. Read more here.
- Gene Network Interactions Shed Insight into Breast Cancer Onset and Developmenton April 18, 2024 at 11:00 am
A new study has identified differential gene-network changes characteristic of the three most prevalent molecular subtypes of breast cancer, Luminal A, Luminal B, and the highly metastatic Basal-like ...
- Immunotherapy Regenerative Medicine Clinic on Using Stem Cells to Activate the Body's Natural Healing Poweron April 18, 2024 at 10:02 am
Stem cell therapy, a cornerstone of regenerative medicine, has shown immense potential in treating autoimmune diseases, aging conditions, and ...
- How AI can help cancer patients receive personalized and precise treatment fasteron April 16, 2024 at 1:35 pm
Providence and Microsoft are developing research prototype AI tools to sort through growing mountains of patient data.
via Bing News